Please use this identifier to cite or link to this item: https://ninho.inca.gov.br/jspui/handle/123456789/5829
Title: DNA Methylation Markers from Negative Surgical Margins Can Predict Recurrence of Oral Squamous Cell Carcinoma
Authors: Sorroche, Bruna Pereira
Talukdar, Fazlur Rahman
Lima, Sheila Coelho Soares
Melendez, Matias Eliseo
Carvalho, Ana Carolina de
Almeida, Gisele Caravina de
Lopes, Monique de Souza Almeida
Pinto, Luis Felipe Ribeiro
Carvalho, André Lopes
Herceg, Zdenko
Arantes, Lidia Maria Rebolho Batista
Marchi, Pedro Rafael Martins De
Keywords: Metilação de DNA
DNA Methylation
Margens de Excisão
Margins of Excision
Carcinoma de Células Escamosas de Cabeça e Pescoço
Squamous Cell Carcinoma of Head and Neck
Recidiva Local de Neoplasia
Neoplasm Recurrence, Local
DNA methylation markers
Marcadores de metilação de DNA
Issue Date: 2021
Publisher: Cancers
Abstract: The identification of molecular markers in negative surgical margins of oral squamous cell carcinoma (OSCC) might help in identifying residual molecular aberrations, and potentially improve the prediction of prognosis. We performed an Infinium MethylationEPIC BeadChip array on 32 negative surgical margins stratified based on the status of tumor recurrence in order to identify recurrence-specific aberrant DNA methylation (DNAme) markers. We identified 2512 recurrenceassociated Differentially Methylated Positions (DMPs) and 392 Differentially Methylated Regions (DMRs) which were enriched in cell signaling and cancer-related pathways. A set of 14-CpG markers was able to discriminate recurrent and non-recurrent cases with high specificity and sensitivity rates (AUC 0.98, p = 3 × 10−6; CI: 0.95–1). A risk score based on the 14-CpG marker panel was applied, with cases classified within higher risk scores exhibiting poorer survival. The results were replicated using tumor-adjacent normal HNSCC samples from The Cancer Genome Atlas (TCGA). We identified residual DNAme aberrations in the negative surgical margins of OSCC patients, which could be informative for patient management by improving therapeutic intervention. This study proposes a novel DNAme-based 14-CpG marker panel as a promising predictor for tumor recurrence, which might contribute to improved decision-making for the personalized treatment of OSCC cases
URI: http://sr-vmlxaph03:8080/jspui/handle/123456789/5829
ISSN: 2072-6694
Appears in Collections:Artigo de Periódicos da Pesquisa Clínica



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.